Osteonecrosis of jaw with the use of denosumab

Journal of Cancer Research and Therapeutics

Volumn 7, Issue 4, 2011, Pages 499-500

  Akhtar, Naveed Hassan ^a   Afzal, Muhammad Zubair ^b   Ahmed, Ali Arslan Aftab ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Department of Internal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ZOLEDRONIC ACID;

ADVANCED CANCER; ALVEOLAR BONE; BONE CANCER; BONE REMODELING; BREAST CANCER; CELL MIGRATION; CELL SURVIVAL; CONNECTIVE TISSUE; EPITHELIUM; HUMAN; INFECTION RISK; JAW OSTEONECROSIS; LETTER; MANDIBLE; MAXILLA; MONOCYTE; OSTEOCLAST; OSTEOLYSIS; OSTEOMYELITIS; PERIOSTEUM; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURGICAL INFECTION; VERTEBRA FRACTURE;

ANTIBODIES, MONOCLONAL; HUMANS; JAW DISEASES; OSTEONECROSIS; RANK LIGAND;

EID: 84856503442     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.92020     Document Type: Letter

References (3)

1. Brown JE, Barrios CH, Diel IJ, Facon T, Fizazi K, Ibrahim T, et al. Incidence and outcomes of Osteonecrosis of the Jaw from an Integrated Analysis of Three Pivotal Randomized Double-Blind, Double-Dummy Phase 3 Trials Comparing Denosumab and Zoledronic Acid for Treatment of Bone Metastases in Advanced Cancer Patients or Myeloma: In: 10th International Conference on Cancer-Induced Bone Disease, 2010 Oct 15.
2. Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: A systematic review and a meta-analysis. Horm Metab Res 2009;41:721-9.
3. Toulis KA, Anastasilakis AD. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int 2010;21:1963-4.